Principal Investigators

    Gideon Davies


    University of York

    Contact information of lead PI


    United Kingdom

    Title of project or programme

    O-GlcNAc as a strategy for the treatment of tauopathies

    Source of funding information

    Alzheimer's Research UK

    Total sum awarded (Euro)

    € 117,580

    Start date of award


    Total duration of award in years



    Research Abstract

    The class of neurodegenerative diseases collectively termed the tauopathies result from the aggregation of a toxic form of tau in with it is hyper(over) phosphorylated. Less well known is that tau phosphorylation is reciprocal to its modification with a sugar termed “O-GlcNAc” and that O-GlcNAc levels are, concomitantly, reduced in the diseased brain. Proof of concept studies show that the toxic form of tau can be significantly reduced using a small molecule strategy that therapeutically raises tau-O-GlcNAc levels.  We aim to study, in detail, the human enzymes responsible for this effect, providing a platform on which to design the next generation of inhibitors providing a new approach to the treatment of tauopathies such as frontotemporal dementia.

    Further information available at:

Types: Investments < €500k
Member States: United Kingdom
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF